Andrew Siderowf is a Neurology physician affiliated with University of Pennsylvania. OpenAlex indexes 363 publications with 30,407 citations (h-index 84). By OpenAlex citation count, this profile ranks in the top 5% of Neurology profiles in the findmyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3400 Spruce Street
2 Ravdin Building
Philadelphia, PA 19104
Telephone
215-662-3606Registry record last updated 19 Apr 2011.
Industry payments
15 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Eli Lilly and CompanyProgram year20257 payments
- Spark Therapeutics, Inc.Program year20252 payments
- F. Hoffmann-La Roche AGProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
NIH funding
4 NIH research awards on record, funded 2000–2022 per NIH RePORTER. The latest:
- University of Pennsylvania Center for the Network of Excellence in Neuroscience Clinical Trials (NeuroNEXT)
University of Pennsylvania
FY2022$294,902U24NS107199 - University of Pennsylvania Center for the Network of Excellence in Neuroscience Clinical Trials (NeuroNEXT)
University of Pennsylvania
FY2021$294,902U24NS107199 - University of Pennsylvania Center for the Network of Excellence in Neuroscience Clinical Trials (NeuroNEXT)
University of Pennsylvania
FY2020$294,902U24NS107199
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Preclinical and clinical evaluation of the LRRK2 inhibitor DNL201 for Parkinson’s disease
Science Translational Medicine
2022 - Neurofilament Light Chain as a Biomarker for Cognitive Decline in Parkinson Disease
Movement Disorders
2021
Similar KOLs
Other experts from the same institution or the same specialty.
Carl June, MD
University of Pennsylvania
Harold Feldman, MD
University of Pennsylvania
Howard Herrmann, MD
University of Pennsylvania
Robert Vonderheide, MD
University of Pennsylvania
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”